ROGApproval•prnewswire•
Roche receives CE IVDR approval for HER2 (4B5) companion diagnostic test to identify HER2-ultralow breast cancer and biliary tract cancer patients
Sentiment:Positive (65)
Summary
(NYSE:ROG) The VENTANA HER2 (4B5) test is now CE-IVDR approved to aid in the assessment of HER2-ultralow status to identify metastatic breast cancer patients who may be eligible for treatment with ENHERTU. The VENTANA HER2 (4B5) test is also now approved to help identify patients with...
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on September 5, 2025 by prnewswire